VARGATEF |
BIBF1120 |
NINTEDANIB |
OFEV |
BIBF-1120 |
INTEDANIB |
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE |
OFEV® |
VARGATEF® |
BIBF 1120 |
drugbank:09079 |
chembl:CHEMBL502835 |
chemidplus:656247-17-5 |
rxcui:1592737 |
pubchem.compound:9809715 |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
Notes |
n/a |
inhibitor (inhibitory) |
Response Type | resistant |
Indication/Tumor Type | urinary bladder cancer |
Evidence Type | Actionable |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | decreased response |
inhibitor (inhibitory) |
Notes | |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
inhibitor (inhibitory) |
Notes | |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
inhibitor (inhibitory) |
Notes | |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | BIBF-1120,Vargatef |
Notes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
BIBF1120 | Development Name |
NINTEDANIB | Generic Name |
VARGATEF | Trade Name |
Drug Class | Kinase Inhibitors |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
CHEMBL502835 | ChEMBL Drug ID |
NINTEDANIB | Primary Drug Name |
VARGATEF | Drug Trade Name |
BIBF 1120 | Drug Synonym |
D09HNV | TTD Drug ID |